Expression of luminal and basal cytokeratins in human breast carcinoma

Journal of Pathology

Volumn 203, Issue 2, 2004, Pages 661-671

  Abd El Rehim, Dalia M ^a   Pinder, Sarah E ^a   Paish, Claire E ^a   Bell, J ^a   Balmey, R W ^a   Robertson, John F R ^a   Nicholson, Robert I ^b   Ellis, Ian ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b Lenovus Institute   (United Kingdom)

Author keywords

Basal and luminal epithelium; Cellular phenotype; Cytokeratin; Immunohistochemistry; Invasive breast cancer; Tissue microarray

Indexed keywords

ALPHA ACTIN; CYTOKERATIN; CYTOKERATIN 14; CYTOKERATIN 18; CYTOKERATIN 19; CYTOKERATIN 5; CYTOKERATIN 6; CYTOKERATIN 7; CYTOKERATIN 8; ESTROGEN RECEPTOR; MONOCLONAL ANTIBODY; PROTEIN SUBUNIT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BASAL CELL; BREAST CARCINOMA; CANCER CLASSIFICATION; CANCER RECURRENCE; CONTROLLED STUDY; DISEASE COURSE; EVIDENCE BASED MEDICINE; FREQUENCY ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; NULL CELL; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN MICROARRAY; RECURRENCE RISK; TUMOR DIFFERENTIATION;

ACTINS; ADOLESCENT; ADULT; AGED; BREAST NEOPLASMS; EPITHELIAL CELLS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-14; KERATIN-5; KERATIN-7; KERATINS; MIDDLE AGED; MUSCLE, SMOOTH; NEOPLASM INVASIVENESS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; PROGNOSIS; RECEPTORS, ESTROGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 2642563617     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1559     Document Type: Article

References (46)

1. Taylor-Papdimitriou J, Lane EB. Keratin expression in the mammary gland. In The Mammary Gland: Development Regulation and Function, Daniel CW (ed). Plenum Press: New York, 1987; 181-215.
2. Cooper D, Schermer A, Sun TT. Classification of human epithelia and their neoplasms using monoclonal antibodies to keratins: strategies, applications, and limitations. Lab Invest 1985; 52: 243-256.
3. Debus E, Weber K, Osborn M. Monoclonal cytokeratin antibodies that distinguish simple from stratified squamous epithelia: characterization on human tissues. Embo J 1982; 1: 1641-1647.
4. Nagle RB, Bocker W, Davis JR, et al. Characterization of breast carcinomas by two monoclonal antibodies distinguishing myoepithelial from luminal epithelial cells. J Histochem Cytochem 1986; 34: 869-881.
5. Bocker W, Moll R, Poremba C, et al. Common adult stem cells in the human breast give rise to glandular and myoepithelial cell lineages: a new cell biological concept. Lab Invest 2002; 82: 737-746.
6. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
7. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-10874.
8. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-410.
9. Ellis IO, Galea M, Broughton N, Locker A, Blamey RW, Elston CW. Pathological prognostic factors in breast cancer. II. Histological type: relationship with survival in a large study with long-term follow-up. Histopathology 1992; 20: 479-489.
10. Pinder SE, Ellis IO, Galea M, O'Rouke S, Blamey RW, Elston CW. Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long-term follow-up. Histopathology 1994; 24: 41-47.
11. Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 1992; 22: 207-219.
12. Blamey RW, Davies CJ, Elston CW, Johnson J, Haybittle JL, Maynard PV. Prognostic factors in breast cancer: the formation of a prognostic index. Clin Oncol 1979; 5: 227-236.
13. Elston CW, Gresham GA, Rao GS, et al. The cancer research campaign (King's/Cambridge trial for early breast cancer: clinicopathological aspects. Br J Cancer 1982; 45: 655-669.
14. Haybittle JL, Blamey RW, Elston CW, et al. A prognostic index in primary breast cancer. Br J Cancer 1992; 45: 361-366.
15. Du Toit RS, Locker AP, Ellis IO, Elston CW, Blamey RW. Evaluation of the prognostic value of triple node biopsy in early breast cancer. Br J Surg 1990; 77: 163-167.
16. Kollias J, Murphy CA, Elston CW, Ellis IO, Robertson IF, Blamey RW. The prognosis of small primary breast cancers. Eur J Cancer 1999; 35: 908-912.
17. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4: 844-847.
18. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest 2000; 80: 1943-1949.
19. Torhorst J, Bucher C, Kononen J, et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 2001; 159: 2249-2256.
20. McCarty KS Jr, Miller LS, Cox EB, Konrath J, McCarty KS Sr. Estrogen receptor analyses: correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 1985; 109: 716-721.
21. Rimm DL, Camp RL, Charette LA, Olsen DA, Provost E. Amplification of tissue by construction of tissue microarrays. Exp Mol Pathol 2001; 70: 255-264.
22. Callagy G, Cattaneo E, Daigo Y, et al. Molecular classification of breast carcinomas using tissue microarrays. Diagn Mol Pathol 2003; 12: 27-34.
23. Ginestier C, Charafe-Jauffret E, Bertucci F, et al. Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers. Am J Pathol 2002; 161: 1223-1233.
24. Rejthar A, Nenutil R. The intermediate filaments and prognostically oriented morphological classification in ductal breast carcinoma. Neoplasma 1997; 44: 370-373.
25. Malzahn K, Mitze M, Thoenes M, Moll R. Biological and prognostic significance of stratified epithelial cytokeratins in infiltrating ductal breast carcinomas. Virchows Arch 1998; 433: 119-129.
26. Altmannsberger M, Dirk T, Droese M, Weber K, Osborn M. Keratin polypeptide distribution in benign and malignant breast tumors: subdivision of ductal carcinomas using monoclonal antibodies. Virchows Arch B Cell Pathol Incl Mol Pathol 1986; 51: 265-275.
27. Dairkee SH, Puett L, Hackett AJ. Expression of basal and luminal epithelium-specific keratins in normal, benign, and malignant breast tissue. J Natl Cancer Inst 1988; 80: 691-695.
28. Jarasch ED, Nagle RB, Kaufmann M, Maurer C, Bocker WJ. Differential diagnosis of benign epithelial proliferations and carcinomas of the breast using antibodies to cytokeratins. Hum Pathol 1988; 19: 276-289.
29. Wetzels RH, Holland R, van Haelst UJ, Lane EB, Leigh IM, Ramaekers FC. Detection of basement membrane components and basal cell keratin 14 in noninvasive and invasive carcinomas of the breast. Am J Pathol 1989; 134: 571-579.
30. Wetzels RH, Kuijpers HJ, Lane EB, et al. Basal cell-specific and hyperproliferation-related keratins in human breast cancer. Am J Pathol 1991; 138: 751-763.
31. Santini D, Ceccarelli C, Taffurelli M, Pileri S, Marrano D. Differentiation pathways in primary invasive breast carcinoma as suggested by intermediate filament and biopathological marker expression. J Pathol 1996; 179: 386-391.
32. van de Rijn M, Perou CM, Tibshirani R, et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 2002; 161: 1991-1996.
33. Takei H, Iino Y, Horiguchi J, et al. Immunohistochemical analysis of cytokeratin #8 as a prognostic factor in invasive breast carcinoma. Anticancer Res 1995; 15: 1101-1105.
34. Schaller G, Fuchs I, Pritze W, et al. Elevated keratin 18 protein expression indicates a favorable prognosis in patients with breast cancer. Clin Cancer Res 1996; 2: 1879-1885.
35. Brotherick I, Robson CN, Browell DA, et al. Cytokeratin expression in breast cancer: phenotypic changes associated with disease progression. Cytometry 1998; 32: 301-308.
36. Adami HO, Malker B, Holmberg L, Pefsson I, Stone B. The relation between survival and age at diagnosis in breast cancer. N Engl J Med 1986; 315: 559-563.
37. Host H, Lund E. Age as a prognostic factor in breast cancer. Cancer 1986; 57: 2217-2221.
38. Ferno M, Borg A, Johansson U, et al. Estrogen and progesterone receptor analyses in more than 4000 human breast cancer samples: a study with special reference to age at diagnosis and stability of analyses. Southern Swedish Breast Cancer Study Group. Acta Oncol 1990; 29: 129-135.
39. Tot T. The cytokeratin profile of medullary carcinoma of the breast. Histopathology 2000; 37: 175-181.
40. Lamovec J, Us-Krasovec M, Zidar A, Kljun A. Adenoid cystic carcinoma of the breast: a histologic, cytologic, and immunohistochemical study. Semin Diagn Pathol 1989; 6: 153-164.
41. Tsuda H, Takarabe T, Hasegawa T, Murata T, Hirohashi S. Myoepithelial differentiation in high-grade invasive ductal carcinomas with large central acellular zones. Hum Pathol 1999; 30: 1134-1139.
42. Tsuda H, Takarabe T, Hasegawa F, Fukutomi T, Hirohashi S. Large, central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases. Am J Surg Pathol 2000; 24: 197-202.
43. Reis-Filho JS, Milanezi F, Paredes J, et al. Novel and classic myoepithelial/stem cell markers in metaplastic carcinomas of the breast. Appl Immunohistochem Mol Morphol 2003; 11: 1-8.
44. Popnikolov NK, Ayala AG, Graves K, Gatalica Z. Benign myoepithelial tumors of the breast have immunophenotypic characteristics similar to metaplastic matrix-producing and spindle cell carcinomas. Am J Clin Pathol 2003; 120: 161-167.
45. Jones C, Nonni AV, Fulford L, et al. CGH analysis of ductal carcinoma of the breast with basaloid/myoepithelial cell differentiation. Br J Cancer 2001; 85: 422-427.
46. Korsching E, Packeisen J, Agelopoulos K, et al. Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest 2002; 82: 1525-1533.